Related Experiment Video

Updated: Jun 4, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K

Advancements in the management of pediatric inflammatory bowel disease

Jonathan E M O'Donnell1,2, Thomas D Walters1,2,3, Eric I Benchimol1,2,3,4,5

  • 1SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Canada.

Expert Review of Gastroenterology & Hepatology
|December 17, 2024
PubMed

Insights

Advances in pediatric inflammatory bowel disease (PIBD) management focus on optimizing therapies and integrating precision medicine. New strategies improve care for children with PIBD, addressing treatment goals and mental health.

Area of Science:

  • Pediatric Gastroenterology
  • Inflammatory Bowel Disease Research

Background:

  • Pediatric inflammatory bowel disease (PIBD) management has evolved significantly over the last decade.
  • Limited availability of novel therapies and concerns regarding long-term efficacy in children have driven innovation.

Purpose of the Study:

  • To review recent advancements in PIBD management.
  • To provide guidance on optimizing biologic therapies, new medical treatments, and adjuvant therapies.
  • To highlight the importance of precision medicine and mental health in PIBD care.

Main Methods:

  • Literature review focusing on recent advances in PIBD management.
  • Synthesis of current guidance on treatment targets and therapeutic strategies.
  • Analysis of emerging therapies, including biologics, small molecules, and microbiome-targeted treatments.

Main Results:

  • Standardized treatment goals using a treat-to-target approach are recommended.
  • Optimizing anti-TNF biologic therapy through combination therapy or proactive drug monitoring is emphasized.
  • Earlier treatment initiation for Crohn's disease and the integration of adjuvant therapies are key advancements.

Conclusions:

  • Future progress in PIBD requires increased pediatric participation in clinical trials for faster drug approval.
  • Integrating precision medicine and mental health screening is crucial for improving patient outcomes.
  • A multidisciplinary approach is essential for comprehensive PIBD care.
Abstract

Keywords:
Inflammatory bowel diseaseadolescentscrohn’s diseasepediatricsprecision medicinetreatmentulcerative colitis

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.8K
Tissue Engineering of the Intestine in a Murine Model08:45

Tissue Engineering of the Intestine in a Murine Model

Published on: December 1, 2012

14.9K

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
111
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
315
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
116
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115